? Alvarium Tiedemann initiated with a Strong Buy at Raymond James 07:28 ALTI
->Cheesecake Factory initiated with a Buy at Northcoast » 07:26 CAKE
->Agco raises FY23 adjusted EPS view to $14.40 from $13.50, consensus $13.60 » 07:25 AGCO
Triple Flag initiated with a Buy at Stifel 16:35 TFPM Stifel initiated coverage of Triple Flag Precious Metals with a Buy rating and C$27 price target. Triple Flag is a precious metals-focused royalty and streaming company with a diversified portfolio and a track record of growth, the analyst tells investors in a research note. The firm says the company has shown robust growth on attributable gold equivalent ounce production and is a "true contender "in the precious metals royalty/streaming space.
Fortinet initiated with a Buy at Rosenblatt 16:06 FTNT Rosenblatt analyst Catherine Trebnick initiated coverage of Fortinet with a Buy rating and $80 price target. The firm's positive thesis is based on Fortinet solutions that it contends are "tailor-fit to the current challenging macro backdrop" and what it sees as the company's "compelling sustainable competitive advantages," the analyst tells investors. Show Related Items >>
FDA conditionally approves first drug for anemia in cats with CKD 14:00 ELAN The U.S. Food and Drug Administration announced it has conditionally approved Varenzin-CA1, the first drug for the control of nonregenerative anemia associated with chronic kidney disease, or CKD, in cats. The FDA granted conditional approval of Varenzin-CA1 to Elanco US Inc.
MoonLake Immunotherapeutics initiated with a Buy at Guggenheim 09:20 MLTX Guggenheim analyst Yatin Suneja initiated coverage of MoonLake Immunotherapeutics with a Buy rating and $51 price target. The firm has a positive view of MoonLake's differentiated IL-17 inhibitor sonelokimab, which is currently in Phase II trials for hidradenitis suppurativa and psoriatic arthritis, the analyst tells investors in a research note. If approved, Guggenheim estimates global peak sales for sonelokimab in HS of over $2B, with additional upside potential driven by success in PsA and additional IL-17-mediated indications.
Formula One Group (FWONK)- I think $77 is the 52 week high// race in Miami this weekend<-------------
NasdaqGS - NasdaqGS Real Time Price.
72.14///////////////////////////////////////////////////
->Cheesecake Factory initiated with a Buy at Northcoast » 07:26 CAKE
->Agco raises FY23 adjusted EPS view to $14.40 from $13.50, consensus $13.60 » 07:25 AGCO
Triple Flag initiated with a Buy at Stifel 16:35 TFPM Stifel initiated coverage of Triple Flag Precious Metals with a Buy rating and C$27 price target. Triple Flag is a precious metals-focused royalty and streaming company with a diversified portfolio and a track record of growth, the analyst tells investors in a research note. The firm says the company has shown robust growth on attributable gold equivalent ounce production and is a "true contender "in the precious metals royalty/streaming space.
Fortinet initiated with a Buy at Rosenblatt 16:06 FTNT Rosenblatt analyst Catherine Trebnick initiated coverage of Fortinet with a Buy rating and $80 price target. The firm's positive thesis is based on Fortinet solutions that it contends are "tailor-fit to the current challenging macro backdrop" and what it sees as the company's "compelling sustainable competitive advantages," the analyst tells investors. Show Related Items >>
FDA conditionally approves first drug for anemia in cats with CKD 14:00 ELAN The U.S. Food and Drug Administration announced it has conditionally approved Varenzin-CA1, the first drug for the control of nonregenerative anemia associated with chronic kidney disease, or CKD, in cats. The FDA granted conditional approval of Varenzin-CA1 to Elanco US Inc.
MoonLake Immunotherapeutics initiated with a Buy at Guggenheim 09:20 MLTX Guggenheim analyst Yatin Suneja initiated coverage of MoonLake Immunotherapeutics with a Buy rating and $51 price target. The firm has a positive view of MoonLake's differentiated IL-17 inhibitor sonelokimab, which is currently in Phase II trials for hidradenitis suppurativa and psoriatic arthritis, the analyst tells investors in a research note. If approved, Guggenheim estimates global peak sales for sonelokimab in HS of over $2B, with additional upside potential driven by success in PsA and additional IL-17-mediated indications.
Formula One Group (FWONK)- I think $77 is the 52 week high// race in Miami this weekend<-------------
NasdaqGS - NasdaqGS Real Time Price.
72.14///////////////////////////////////////////////////
